The companies would collaborate to develop a pre-clinical gene therapy candidate for Huntington’s disease (HD), an inherited condition that causes nerve cells in parts of the brain to gradually break down and die.
Featured Posts
Elpiscience Biopharma, Ltd. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019, and another program.
A man may regain the use of his hand, left paralysed by a severe road accident, thanks to a pioneering nerve transfer operation from his partly amputated leg, doctors in northern Italy said.
Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
The U.S. Food and Drug Administration has placed a clinical hold on Iovance Biotherapeutics’ lung cancer therapy trial after a patient death, the company said on Wednesday.
A thick layer of toxic smog wreathed Bangladesh’s capital of Dhaka on Wednesday as the air quality index plummeted into the “hazardous” category, while similar conditions prevailed in New Delhi, the capital of neighboring India.
Amgen announced that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s supplemental New Drug Application seeking full approval of LUMAKRAS® (sotorasib).
Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less than a week.
AstraZeneca said on Tuesday it will buy Gracell Biotechnologies for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world’s second-largest pharmaceuticals market.
Zealand Pharma said on Saturday that the U.S. Food and Drug Administration (FDA) had declined to approve its drug for preventing and treating low blood sugar in children with a genetic disorder after finding deficiencies at a third-party manufacturing facility.